Stories from people navigating TMB-high solid tumors — diagnosis, treatment, caregiving, and the ordinary days in between.
2 stories
Clinical Briefs
Traditional approval retains a narrow, tissue-agnostic indication for adults and children with previously treated, unresectable or metastatic TMB-high solid tumors and no satisfactory alternatives.
Rayan Salih · October 28, 2026 · 6 min
Oncology
FDA traditional approval defines TMB-high solid tumors as at least 13 mutations per megabase. Eligibility depends on confirming that the reported result meets the new cutoff.
Rayan Salih · 7 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.